Trials / Recruiting
RecruitingNCT05341557
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Betta Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPI-371153 | Subjects will receive BPI-371153 until disease progression |
Timeline
- Start date
- 2022-08-29
- Primary completion
- 2026-12-01
- Completion
- 2027-04-01
- First posted
- 2022-04-22
- Last updated
- 2025-01-27
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05341557. Inclusion in this directory is not an endorsement.